Overview

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Status:
Not yet recruiting
Trial end date:
2024-11-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether daily treatment with SHR3680 affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC).
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.